Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vitrolife ABCHIX:VITRS 80 PS Ratio is 4.21 as of Jul. 15, 2026, which is 66% below its 10-year median of 12.48. GuruFocus rates CHIX:VITRS with a GF Score™ of 80/100 and a GF Value™ of kr163.55 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 805 Medical Devices & Instruments companies, Vitrolife AB ranks worse than 57.52% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Vitrolife AB's share price is kr105.75.
Vitrolife AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was kr25.14. Hence, Vitrolife AB's PS Ratio for today is 4.21.
Good Sign:
Vitrolife AB stock PS Ratio (=3.46) is close to 10-year low of 3.46.
The historical rank and industry rank for Vitrolife AB's PS Ratio or its related term are showing as below:
CHIX:VITRs'
s PS Ratio Range Over the Past 10 Years
Min: 3.46 Med: 12.48 Max: 39.95
Current: 3.46
During the past 13 years, Vitrolife AB's highest PS Ratio was 39.95. The lowest was 3.46. And the median was 12.48.
CHIX:VITRs's PS Ratio is ranked worse than 57.52% of 805
companies
in the Medical Devices & Instruments industry
Industry Median: 2.88
vs CHIX:VITRs: 3.46
Vitrolife AB revenue per share is in decline over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Vitrolife AB was -5.60% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 2.10% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 18.20% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 15.90% per year.
During the past 13 years, Vitrolife AB's highest 3-Year average Revenue per Share Growth Rate was 31.20% per year. The lowest was 2.10% per year. And the median was 17.50% per year.
Back to Basics: PS Ratio
Vitrolife AB (CHIX:VITRs) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Vitrolife AB PS Ratio Related Terms
Vitrolife AB PS Ratio Historical Data
* Premium members only.
The historical data trend for Vitrolife AB's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Vitrolife AB's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vitrolife AB PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Vitrolife AB's PS Ratio distribution charts can be found below:
* The bar in red indicates where Vitrolife AB's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Vitrolife AB's PS Ratio for today is calculated as
Vitrolife AB's Share Price of today is kr105.75. Vitrolife AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr25.14.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Vitrolife AB (CHIX:VITRS) has a PS Ratio of 4.21 as of Jul. 15, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Vitrolife AB and its competitors. This is 66% below median its historical median of 12.48. Over the past decade, Vitrolife AB's PS Ratio has ranged from 3.46 to 39.95. According to the industry distribution chart, Vitrolife AB ranks #463 out of 805 companies in the Medical Devices & Instruments industry, placing it in the top 57.5%.
Is Vitrolife AB's PS Ratio too high?
Vitrolife AB's current PS Ratio of 4.21 is 66% below median its 10-year median of 12.48. Over the past 10 years, this metric has ranged from a low of 3.46 to a high of 39.95. The Medical Devices & Instruments industry median PS Ratio is 2.88. Vitrolife AB's value of 4.21 is 46.2% above this industry median. Based on the distribution chart, Vitrolife AB ranks #463 out of 805 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Vitrolife AB has a GF Score™ of 80/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vitrolife AB's PS Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Vitrolife AB ranks #463 out of 805 companies for PS Ratio. This places Vitrolife AB in the lower half of its industry. The industry median PS Ratio is 2.88. Vitrolife AB's value of 4.21 is 46.2% above this benchmark. Historically, Vitrolife AB's own PS Ratio has ranged from 3.46 to 39.95 over the past decade. While the company's 10-year median is 12.48 vs. the industry median of 2.88, Vitrolife AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Devices & Instruments company?
The median PS Ratio among Medical Devices & Instruments companies is 2.88, based on 805 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vitrolife AB's current PS Ratio of 4.21 is 46.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Vitrolife AB and its competitors. For the Medical Devices & Instruments industry, the median PS Ratio is 2.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vitrolife AB's current PS Ratio is 4.21, which is 66% below median its own 10-year median of 12.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vitrolife AB stock overvalued right now?
Based on GuruFocus' analysis, Vitrolife AB (CHIX:VITRS) is currently considered Possible Value Trap. The stock's GF Value™ is kr163.55, compared to a current price of kr105.75 — trading 35.3% below its estimated fair value. The current PS Ratio is 4.21, which is 66% below median its 10-year median of 12.48 and 46.2% above the Medical Devices & Instruments industry median of 2.88. Vitrolife AB's overall GF Score™ is 80/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Vitrolife AB (CHIX:VITRS), the current PS Ratio is 4.21 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vitrolife AB (CHIX:VITRS) Overvalued in 2026?
Based on GuruFocus' analysis, Vitrolife AB stock appears to be undervalued.
The current stock price of kr105.75 is trading 35.3% below its estimated GF Value™ of kr163.55.
GuruFocus considers Vitrolife AB to be Possible Value Trap.
Key valuation signals for CHIX:VITRS:
PS Ratio: 4.21 (66% below median its 10-year median of 12.48)
GF Value™: kr163.55 vs. price of kr105.75 (35.3% below fair value)
Industry Position: 46.2% above the Medical Devices & Instruments median (#463 of 805)
No single metric tells the full story. See the CHIX:VITRS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vitrolife AB provides medical devices and genetic testing services intended for the reproductive-health market in the field of reproductive health. The company develops, manufactures, and distributes medical devices and provides genetic testing services for IVF clinics and their patients. Its mission is to support IVF clinics (in vitro fertilization) in enhancing their practice as well as the outcome of a patient's fertility treatment, thereby enabling patients to receive support to navigate the complexities of reproductive health through successful outcomes and patient satisfaction. The company has three geographical segments EMEA, Americas and APAC, out of which it derives maximum revenue from EMEA.
80GF Score
Get the complete analysis for CHIX:VITRS
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:VITRS has been successfully added to your 
